Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, has successfully secured approximately $7.3 million in gross proceeds through a combination of direct offerings and private placements. The company, which specializes in developing therapies for neurodegenerative diseases, announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor.
Under the terms of the agreement, Clene will issue and sell 742,626 shares of common stock, or prefunded warrants in lieu thereof. Additionally, the company has entered into separate agreements with current investors, as well as directors and officers of Clene, for further placements. These transactions are expected to close on or about October 1, 2024, with Canaccord Genuity acting as the sole placement agent for the offerings.
This influx of capital comes at a crucial time for Clene, as the company continues to advance its research and development efforts in the field of neurodegenerative diseases. Clene’s primary focus is on improving mitochondrial health and protecting neuronal function to treat conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis.
The company’s flagship investigational therapy, CNM-Au8®, is a first-in-class treatment that aims to enhance the survival and function of central nervous system cells. This innovative approach targets mitochondrial function and the nicotinamide adenine dinucleotide (NAD) pathway while simultaneously reducing oxidative stress. CNM-Au8 has shown promise in addressing the underlying cellular mechanisms involved in neurodegenerative diseases.
The successful fundraising effort underscores the confidence investors have in Clene’s potential to make significant strides in treating these challenging neurological conditions. The additional capital will likely be used to support ongoing clinical trials, further research and development initiatives, and potentially accelerate the company’s path toward bringing its therapies to market.
For patients suffering from neurodegenerative diseases and their families, Clene’s progress represents hope for potential new treatment options. The development of therapies that target mitochondrial health and neuronal function could lead to improved outcomes and quality of life for those affected by these debilitating conditions.
As Clene continues to advance its clinical programs, the biopharmaceutical industry will be closely watching the results of its ongoing studies. Success in this field could not only benefit Clene but also pave the way for new approaches to treating neurodegenerative diseases across the sector.
With its headquarters in Salt Lake City, Utah, and R&D and manufacturing operations in Maryland, Clene is well-positioned to leverage its resources and expertise in the pursuit of groundbreaking therapies. The company’s focus on CNM-Au8, a federally registered trademark of Clene Nanomedicine, demonstrates its commitment to innovative solutions in the fight against neurodegenerative diseases.
As the closing date for the offerings approaches, stakeholders in the biotech and healthcare sectors will be keenly observing Clene’s next moves. The successful completion of this funding round marks a significant milestone for the company and potentially brings it one step closer to realizing its mission of improving the lives of patients with neurodegenerative diseases.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Clene Inc. Secures $7.3 Million in Funding Through Direct Offerings and Private Placements.